How gastric bypass rapidly reverses diabetes symptoms
|
|
A report in the September Cell Metabolism, a publication of Cell Press, offers new evidence to explain why those who undergo gastric bypass surgery often show greater control of their diabetes symptoms within days. It also helps to explain why lap-band surgery doesn’t offer the same instant gratification. By studying mice that have undergone both procedures, the researchers show that changes in the intestine are the key.
In addition to removing about two-thirds of the stomach, gastric bypass in effect produces a “double intestine,” said Gilles Mithieux of Institut National de la Sante et de la Recherche Medicale in France. The portion closest to the stomach is taken out of the loop so that it receives no nutrients. The segment normally farther down is then attached directly to the stomach, where it receives all the nutrients coming in.
In both cases, those positional changes ramp up production of blood sugar by the small intestine, Mithieux said. He noted that fasting normally induces blood sugar production by the upper small intestine. By placing the lower small intestine, which doesn’t normally produce much glucose, in close proximity to the stomach, it starts to act more like the upper portion.
That blood sugar synthesized in the intestine pours into the portal vein (a large vein that carries blood from the digestive tract to the liver) where it sends a signal to the brain, he and his colleagues earlier found. “The walls of the portal vein system detect the glucose and inform the brain,” he said. “It’s an important signal for decreasing hunger.”
They now find an important new element of glucose production by the intestine. It also increases insulin sensitivity and lowers blood sugar, improving the symptoms of diabetes. Mithieux said that’s in part because glucose production by the intestine lowers glucose production by the liver, which accounts for a much greater overall proportion of blood sugar synthesis. These metabolic changes take place within days of surgery, well before any weight loss takes place.
While gastric banding, in which a prosthetic band is placed around the upper stomach, works for weight loss, it doesn’t affect the intestine at all and lacks the immediate metabolic benefits of bypass, they report.
Further evidence for the mechanism involved came from studies of mice lacking GLUT-2, a glucose transporter required for glucose sensing in the portal vein. Gastric bypass lost its insulin-sensitizing benefits in those GLUT-2-deficient mice. Similarly, mice whose portal veins had lost their nerve supply also stopped responding to the surgical procedure.
The bottomline, according to Mithieux: the intestine deserves more respect. “Up to now, the intestine had been considered like a machine to assimilate nutrients. We’ve now begun to realize that it is a complex endocrine organ” with particular importance when it comes to glucose metabolism.
As for what patients weighing gastric bypass versus lap-band surgery should do, Mithieux recommends they talk to their doctors about the possible benefits and risks of both procedures. The new findings do support the notion that gastric bypass may be an effective treatment for diabetes in obese patients. It might even have potential for people who are diabetic, whether they are obese or not, he said.
###
The researchers include Stephanie Troy, Institut National de la Sante et de la Recherche Medicale, Faculte´ de Medecine Xavier Bichat, Universite Paris, Paris, France; Maud Soty, Institut National de la Sante et de la Recherche Medicale, Lyon, France, Universite de Lyon, Lyon, France, Universite Lyon, Villeurbanne, France; Lara Ribeiro, Institut National de la Sante et de la Recherche Medicale, Faculte´ de Medecine Xavier Bichat, Universite Paris, Paris, France; Laure Laval, Institut National de la Sante et de la Recherche Medicale, Lyon, France, Universite de Lyon, Lyon, France, Universite Lyon, Villeurbanne, France; Stephanie Migrenne, Universite´ Paris, Paris, France; Xavier Fioramonti, Universite´ Paris, Paris, France; Bruno Pillot, Institut National de la Sante et de la Recherche Medicale, Lyon, France, Universite de Lyon, Lyon, France, Universite Lyon, Villeurbanne, France; Veronique Fauveau, Institut Cochin, Faculte´ de Medecine Cochin, Paris, France; Roberte Aubert, Institut National de la Sante et de la Recherche Medicale, Faculte´ de Medecine Xavier Bichat, Universite Paris, Paris, France; Benoit Viollet, Institut Cochin, Universite´ Paris Descartes, CNRS, Paris, France, Inserm, U567, Paris, France; Marc Foretz, Institut Cochin, Universite´ Paris Descartes, CNRS, Paris, France, Inserm, U567, Paris, France; Jocelyne Leclerc, Institut Cochin, Universite´ Paris Descartes, CNRS, Paris, France, Inserm, U567, Paris, France; Adeline Duchampt, Institut National de la Sante et de la Recherche Medicale, Lyon, France, Universite de Lyon, Lyon, France, Universite Lyon, Villeurbanne, France; Carine Zitoun, Institut National de la Sante et de la Recherche Medicale, Lyon, France, Universite de Lyon, Lyon, France, Universite Lyon, Villeurbanne, France; Bernard Thorens, University of Lausanne, Lausanne, Switzerland; Christophe Magnan, Universite´ Paris, Paris, France; Gilles Mithieux, Institut National de la Sante et de la Recherche Medicale, Lyon, France, Universite de Lyon, Lyon, France, Universite Lyon, Villeurbanne, France; and Fabrizio Andreelli, Institut National de la Sante et de la Recherche Medicale, Faculte´ de Medecine Xavier Bichat, Universite Paris, Paris, France, CHU Bichat Claude Bernard, Service de Diabetologie-Endocrinologie-Nutrition, Paris, France.
Contact: Cathleen Genova
.(JavaScript must be enabled to view this email address)
617-397-2802
Cell Press
Print Version
Tell-a-Friend comments powered by Disqus
